We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+6.82%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$671M
AUM Growth
-$749M
Cap. Flow
-$596M
Cap. Flow %
-88.74%
Top 10 Hldgs %
41.79%
Holding
248
New
39
Increased
16
Reduced
53
Closed
62

Top Buys

Rank Stock Value
1
KZR
Kezar Life Sciences
KZR
+$11.5M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$7.64M
3
CLDX icon
Celldex Therapeutics
CLDX
+$6.48M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$5.45M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.08M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$13.7M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$7.89M
3
CMPS
Compass Pathways
CMPS
+$6.85M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$5.93M
5
BCAB icon
BioAtla
BCAB
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 50.73%
2 Consumer Staples 0.3%
3 Technology 0.3%
4 Financials 0.11%
5 Real Estate 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
26
Vaxcyte
PCVX
$7.65B
$7.02M 1.05%
295,111
– –
MCRB icon
27
Seres Therapeutics
MCRB
$45M
$6.63M 0.99%
39,795
+9,467
+31% +$1.5M
PRDS
28
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$6.55M 0.98%
+400,000
New +$4.65M
INBX
29
DELISTED
Inhibrx, Inc. Common Stock
INBX
$6.54M 0.97%
149,850
-140,000
-48% -$5.6M
AYLA
30
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
$5.7M 0.85%
669,271
+130,332
+24% +$1.29M
XENE icon
31
Xenon Pharmaceuticals
XENE
$6.1B
$5.6M 0.83%
179,138
-198,300
-53% -$5.93M
RETA
32
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.27M 0.79%
200,000
+90,400
+82% +$7M
XFOR icon
33
X4 Pharmaceuticals
XFOR
$377M
$5.19M 0.77%
75,483
-9,181
-11% -$1.16M
CMRX
34
DELISTED
Chimerix, Inc.
CMRX
$5.11M 0.76%
795,410
-5,898
-0.7% -$35.4K
RCUS icon
35
PUT
Arcus Biosciences
RCUS
$3.33B
$5.04M 0.75%
+124,600
New +$4.83M
LKFT
36
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$4.86M 0.72%
86,865
– –
GBT
37
DELISTED
Global Blood Therapeutics, Inc.
GBT
$4.8M 0.72%
+164,082
New +$5.08M
WHWK
38
Whitehawk Therapeutics
WHWK
$181M
$4.74M 0.71%
196,408
+185,000
+1,622% +$4.65M
SCPH
39
DELISTED
scPharmaceuticals
SCPH
$4.53M 0.67%
901,362
– –
PTGX icon
40
CALL
Protagonist Therapeutics
PTGX
$8.55B
$4.34M 0.65%
126,900
+65,800
+108% +$2.08M
IOVA icon
41
PUT
Iovance Biotherapeutics
IOVA
$2.04B
$3.74M 0.56%
196,000
– –
CABA icon
42
Cabaletta Bio
CABA
$427M
$3.68M 0.55%
970,398
-217,500
-18% -$2.32M
IBB icon
43
iShares Biotechnology ETF
IBB
$9.45B
$3.67M 0.55%
+24,022
New +$3.72M
INBX
44
CALL
DELISTED
Inhibrx, Inc. Common Stock
INBX
$3.53M 0.53%
+80,800
New +$3.23M
ACET icon
45
CALL
Adicet Bio
ACET
$77.6M
$3.5M 0.52%
+12,500
New +$2.15M
NKTR icon
46
CALL
Nektar Therapeutics
NKTR
$2.39B
$3.38M 0.5%
16,667
+9,014
+118% +$1.96M
IOVA icon
47
Iovance Biotherapeutics
IOVA
$2.04B
$3.29M 0.49%
172,521
– –
FNCH
48
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
$3.15M 0.47%
10,524
– –
WVE icon
49
Wave Life Sciences
WVE
$1.12B
$3.12M 0.46%
993,481
– –
CLVS
50
DELISTED
Clovis Oncology, Inc.
CLVS
$3.02M 0.45%
1,112,669
– –
1
2
3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Ikarian Capital held 248 positions worth $671M, down 53% from $1.42B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Ikarian Capital withdrew a net $596M in Q4 2021, closing 62 positions and reducing 53 holdings. Its most notable exit was Apellis Pharmaceuticals, an estimated $13.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 30% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Ikarian Capital opened a new position in Kezar Life Sciences worth $17.1M.

  • Ikarian Capital's largest Q4 2021 buy was Kezar Life Sciences: 102,092 shares worth $17.1M.
  • Ikarian Capital added most to Zentalis Pharmaceuticals in Q4 2021, an estimated $7.64M increase.
  • Ikarian Capital's biggest Q4 2021 reduction was Xenon Pharmaceuticals, cutting an estimated $5.93M.
  • Ikarian Capital fully exited Apellis Pharmaceuticals in Q4 2021, selling an estimated $13.7M.
  • Ikarian Capital's ten largest holdings make up 42% of its $671M portfolio in Q4 2021.
  • Ikarian Capital opened 39 new positions and closed 62 in Q4 2021.
  • Ikarian Capital's portfolio value fell 53% quarter-over-quarter to $671M.

Based on Ikarian Capital's 13F filing for Q4 2021, filed 14 Feb 2022.